Projecting future drug expenditures - 2002

American Journal of Health-System Pharmacy

Volumn 59, Issue 2, 2002, Pages 131-142

  Shah, Nilay D ^a   Vermeulen, Lee C ^a   Santell, John P ^a   Hunkler, Robert J ^a   Hontz, Karrie ^a  

^a University of Wisconsin Health   (United States)

Author keywords

Costs; Drug use; Economics; Health care; Prescriptions; Pricing

Indexed keywords

ABARELIX; AGALSIDASE ALFA; AGALSIDASE BETA; AMOXICILLIN PLUS CLAVULANIC ACID; ARIPIPRAZOLE; AZIMILIDE; AZITHROMYCIN; BEXAAR; BOSENTAN; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; DESLORATADINE; DOCETAXEL; DROTRECOGIN; EFALIZUMAB; ELETRIPTAN; ENZYME; EPLERENONE; ERTAPENEM; ETORICOXIB; FLUCONAZOLE; FLUOXETINE; FONDAPARINUX; GABAPENTIN; GEFITINIB; IBRITUMOMAB TIUXETAN; ILOPERIDONE; INFLUENZA VACCINE; ISOTRETINOIN; LEVOSIMENDAN; LISINOPRIL; LORATADINE; MILRINONE; MONOCLONAL ANTIBODY; NABUMETONE; NIZATIDINE; OMALIZUMAB; OMAPATRILAT; OMEPRAZOLE; ONDANSETRON; OXALIPLATIN; PARATHYROID HORMONE[1-34]; PARECOXIB; PEMETREXED; PIMECROLIMUS; PRAMLINTIDE; PRASTERONE; RASBURICASE; REBOXETINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ROSUVASTATIN; TADALAFIL; TEGASEROD; TELITHROMYCIN; TIBOLONE; TIOTROPIUM BROMIDE; UFT; UNCLASSIFIED DRUG; UNINDEXED DRUG; UNIPROST; VORICONAZOLE;

AMBULATORY CARE; DRUG APPROVAL; DRUG COST; DRUG MARKETING; ECONOMIC ASPECT; HEALTH CARE COST; HOSPITAL; OUTPATIENT DEPARTMENT; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SEPSIS; TECHNOLOGY; UNITED STATES;

EID: 0037081977     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/59.2.131     Document Type: Review

References (30)

1. Tracking health care costs: Inflation returns
2. Business watch 2001 in review: Growth slows, but goes on
3. IMS HEALTH national prescription audit
4. Direct-to-consumer prescription drug advertising: Trends, impact, and implications
5. 2000 DTC spend hits $2.28 B led by Vioxx, Prilosec
6. FDA is investigating any correlation between increased number of prescriptions written in the US and increased advertising by pharmaceutical companies; consumer advertising by drug companies totaled $2.5 bil in 2000
7. The retail value of drug samples received in doctors' offices in 1996 totaled $4.9 bil, up 9.8% from 1995
8. Delayed reaction: Drug manufacturers step up legal attacks that slow generics
9. FTC accuses drug makers of collusion to delay generics
10. IMS HEALTH retail provide perspective
11. The patients are paying the price. A look at the human cost of the FDA's decision to speed drug approvals
12. Two companies get bad news from F.D.A. on new drug
13. Zelnorm rejection should not cause Novartis more pain
14. Firm faces summertime blues. Eli Lilly is losing its Prozac patent
15. Waiting to inhale - Maker of breathable insulin takes big hit. Market reacts to possible delay in FDA approval
16. The birth of a cancer drug. After more than 20 years and $100 million, IMC-225 is awaiting FDA approval. Will ImClone's big effort pay off?
17. Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industry